Akums Drugs and Pharmaceuticals has approved an advanced triple combination diabetes treatment, including Sitagliptin 100, Pioglitazone 15, and Metformin 1000/500. This treatment offers more efficacy and precision than current monotherapy drugs and includes active formulations like Metformin for Type-2 diabetes.

Pioglitazone, a triple-active combination, is effective against Type-2 diabetes by improving insulin sensitivity, lowering HbA1c levels, and promoting lipid metabolism and insulin secretion. It is combined with Sitagliptin, which significantly reduces HbA1c levels when used with insulin, sulfonylureas, thiazolidinediones, or alone with or without metformin.

Akums Drugs & Pharmaceuticals has found the right blend for this triple-active combination, allowing better treatment for patients without swallowing multiple drugs. The approval boosts patient convenience and dosage compliance, demonstrating the drug's suitability for patients seeking relief from Type-2 diabetes.

The approved bi-layered combination follows thorough research and adheres to pharmacological guidelines. It offers effective diabetes treatment with metformin, pioglitazone, and Sitagliptin. “As a brand, we will continue to introduce new combinations to help patients around the world get better,” said Sanjeev Jain, Managing Director, Akums Drugs & Pharmaceuticals.